First Keytruda biosimilars move into clinical trials as Merck pushes ahead with new formulation
At least three companies have started or are about to start trials of Keytruda biosimilars in what’s expected to create a wave of less expensive …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
